78156-39-5

Basic information

• Product Name: 3-BROMO-5-METHOXYPYRIDINE-1-OXIDE
• Synonyms: 3-BROMO-5-METHOXYPYRIDINE-1-OXIDE
• CAS NO: 78156-39-5
• Molecular Formula: C₆H₆BrNO₂
• Molecular Weight: 204.02
• Mol File: 78156-39-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-BROMO-5-METHOXYPYRIDINE-1-OXIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-5-METHOXYPYRIDINE-1-OXIDE(78156-39-5)
• EPA Substance Registry System: 3-BROMO-5-METHOXYPYRIDINE-1-OXIDE(78156-39-5)

Safety Data

• Hazardous Substances Data: 78156-39-5(Hazardous Substances Data)

Usage

General Description

3-Bromo-5-methoxypyridine-1-oxide is a chemical compound with the molecular formula C6H5BrNO2. It is a pyridine derivative that contains a bromine atom and a methoxy group attached to the five position of the pyridine ring, as well as a nitroso group attached to the one position. 3-BROMO-5-METHOXYPYRIDINE-1-OXIDE is primarily used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It also has potential applications in organic synthesis, medicinal chemistry, and material science. The presence of the nitroso group makes it an interesting building block for the preparation of diverse functionalized pyridine derivatives. Additionally, its unique structure and reactivity make it an important tool for researchers in the field of organic and medicinal chemistry.

Upstream product

• 50720-12-2 3-bromo-5-methoxypyridine 
• 93-59-4 Perbenzoic acid 
• 625-92-3 3,5-dibromopyridine 
• 937-14-4 3-chloro-benzenecarboperoxoic acid 
• 67-56-1 methanol 
• 2402-99-5 3,5-dibromopyridine-N-oxide 

Downstream Products

• 78156-40-8 3-amino-5-methoxypyridine N-oxide 
• 42409-58-5 5-bromo-3-methoxy-pyridin-2-amine 
• 1379325-16-2 3-bromo-5-methoxypyridin-2-amine 
• 1581767-46-5 2-ethoxy-3-methoxy-6-bromo-5-(4-fluorophenyl)pyridine 
• 1469896-37-4 2-ethoxy-3-methoxy-5-(4-fluorophenyl)pyridine 
• 1581767-04-5 6-bromo-5-(4-fluorophenyl)-3-hydroxypyridin-2(1H)-one 

Relevant articles and documents

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

An efficient, regioselective amination of 3,5-disubstituted pyridine N-oxides using saccharin as an ammonium surrogate

A process for the regioselective amination of unsymmetrical 3,5-substituted pyridine N-oxides has been developed utilizing cheap, readily available saccharin as an ammonium surrogate. High conversions of the corresponding saccharin adducts have been achieved under mild reaction conditions. In situ deprotection under acidic conditions allows for a one-pot process to substituted aminopyridines. High regioselectivities were obtained from a variety of 3,5-disubstituted pyridine N-oxides.

UREA DERIVATIVE HAVING PI3K INHIBITORY ACTIVITY

Provided is a compound or a pharmaceutically acceptable salt thereof which inhibits the activity of PI3K to regulate many biological processes including the growth, differentiation, survival, proliferation, migration, metabolism, and the like of cells and is therefore useful for the prophylaxis/therapy of diseases including inflammatory diseases, arteriosclerosis, vascular/circulatory diseases, cancer/tumors, immune system diseases, cell proliferative diseases, infectious diseases, and the like. The above problem was solved by providing a urea derivative shown in the present specification, or a pharmaceutically acceptable salt thereof.